PIK3CA and cancer: A major discrepancy can be seen, as TP53 presented a higher mutation rate in L_cancer (L_cancer, 68%; R_cancer, 48%), while PIK3CA (L_cancer, 18%; R_cancer, 33%) and KRAS (L_cancer, 36%; R_cancer, 46%) showed higher yield mutation rates in R_cancer.